enGene (Nasdaq: ENGN) Launched as Publicly Traded Genetic Medicines Company

 Business combination transaction completed with Forbion European Acquisition Corp.

Clinical stage biotechnology company with EG-70 lead program in pivotal clinical study targeting BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)

$138M in gross proceeds from transaction to support advancement of EG-70 clinical program, which is currently enrolling patients, and continued pipeline expansion in additional therapeutic areas

https://www.prnewswire.com/news-releases/engene-nasdaq-engn-launched-as-publicly-traded-genetic-medicines-company-301973481.html